Drugs / BT5528
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04075175 | Apr → Oct 2019 | diphtheria | MassBiologics | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04180371 | Nov 2019 → Jul 2026 overdue | gastroesophageal cancer, head and neck cancer, non-small cell lung carcinoma, ovarian cancer +2 | BicycleTx Limited | Active not recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07681674 | Aug 2026 → May 2030 expected | cancer | BicycleTx Limited | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07450859 | Mar 2026 → Mar 2029 expected | pancreatic ductal adenocarcinoma | BicycleTx Limited | Recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BT5528 | “nuzefatide pevedotin (BT5528)” NCT07450859 ↗ |
| Known as | Nuzefatide pevedotin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07681674 ↗ |
| Known as | S315 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04075175 ↗ |
| Action | Inhibit | “S315 is a fully human, monoclonal immunoglobulin G1 neutralizing antibody, specific to the receptor-binding domain of diphtheria toxin.” PMID 39570031 ↗ Sep 2025 |
| Modality | Monoclonal antibody | “S315 is a fully human, monoclonal immunoglobulin G1 neutralizing antibody, specific to the receptor-binding domain of diphtheria toxin.” PMID 39570031 ↗ Sep 2025 |
| Route | Intravenous | “single intravenous infusions of S315” PMID 39570031 ↗ Sep 2025 |
| Target | EPHA2 | “binds to EphA2” NCT04180371 ↗ |